Pacira Pharmaceuticals has reported positive results from a Phase III study of Exparel in patients who had undergone excisional hemorrhoidectomy using the Milligan-Morgan technique, a painful soft tissue surgery.

The multicentre, randomised, double-blind, parallel-group, placebo-controlled study included 189 patients and showed that 94.7% of patients treated with Exparel were satisfied with their post-surgical analgesia, compared with 73.9% in the placebo group.

The drug reported reduction in cumulative pain score and a reduction in opioid use in the patients.

Adverse events seen with the use of Exparel include nausea, constipation, and vomiting.